FOXO4-DRI

FOXO4-DRI is a synthetic peptide that targets and eliminates aged or damaged cells by disrupting the FOXO4–p53 interaction, promoting apoptosis specifically in senescent cells while sparing healthy ones. By reducing senescent cell burden and the SASP milieu, it shows promise for anti-aging, tissue rejuvenation, and mitigation of age-related disease.

- Promote cellular longevity and reduce senescent cell accumulation

- Support tissue regeneration, cognitive health, and recovery

Mechanism of Action

How this peptide works in the body

p53 Pathway Reactivation:

FOXO4-DRI disrupts the interaction between FOXO4 and p53, which normally prevents apoptosis in senescent cells. By freeing p53 from FOXO4 binding, it enables p53 to translocate to the mitochondria, where it activates pro-apoptotic proteins BAX and PUMA. This leads to mitochondrial membrane depolarization, cytochrome c release, and caspase activation, ultimately triggering selective apoptosis of senescent cells while sparing healthy ones.

Senescence Clearance:

FOXO4-DRI induces apoptosis in senescent cells, particularly those expressing high levels of the senescence-associated secretory phenotype (SASP). By reducing the secretion of pro-inflammatory cytokines (IL-6, IL-8, TNF-α) and growth factors like granulocyte-macrophage colony-stimulating factor (GM-CSF), it helps reduce chronic inflammation and prevent age-related tissue damage.

Insulin and Oxidative Stress Regulation:

By modulating the AKT, FOXO1, and MAPK pathways, FOXO4-DRI improves insulin sensitivity and enhances metabolic efficiency. It also reduces oxidative damage by increasing cellular antioxidant responses, protecting tissues from age-related metabolic dysfunction and oxidative stress-induced apoptosis.